America's Business to Business Journal for Industry

Expansion for Catalent Pharma Solutions in Winchester; Company to Add 90 Jobs

Catalent plans to invest $35 million and nearly double current facility

WINCHESTER, Ky. -- Catalent Pharma Solutions LLC is expanding operations, adding 90 jobs and investing more than $35 million in the project. To meet increased industry demand, the company is adding 80,000 square feet to its current 100,000-square-foot facility on Enterprise Drive in Winchester.  

Catalent is a global leader in development solutions and advanced drug delivery technologies, providing worldwide clinical and commercial supply capabilities for drugs, biologics and consumer health products. The company employs approximately 8,500 people, including more than 1,000 scientists, at nearly 30 facilities on five continents.

Opened in 1992, the Winchester plant currently employs more than 300 people and produces a variety of over-the-counter and prescription drugs in tablet, capsules and powders. The facility has launched more than 100 products for Catalent’s pharmaceutical and consumer health customers. Catalent expects to complete the expansion of the facility by October 2014.

“Catalent is a fully integrated formulation, regulatory, and manufacturing solutions partner, helping pharmaceutical and consumer healthcare companies differentiate their products and reach markets faster,” said John Chiminski, president and CEO of Catalent Pharma Solutions. 

“Catalent has been present at this site for over 20 years developing and manufacturing important medicines,” said Steve Havel, general manager of Catalent’s Winchester facility. “Our commitment to Kentucky is illustrated by the expansion of our Winchester facility, which will provide our customers with more capabilities to help develop and manufacture new products.”  

To encourage the investment and job growth in Winchester, the Kentucky Economic Development Finance Authority (KEDFA) preliminarily approved the company for tax incentives up to $2 million through the Kentucky Business Investment program. The performance-based incentive allows a company to keep a portion of its investment over the term of the agreement through corporate income tax credits and wage assessments by meeting job and investment targets. 

KEDFA also approved Catalent for tax benefits up to $860,000 through the Kentucky Enterprise Initiative Act, which allows approved companies to recoup Kentucky sales and use tax on construction costs, building fixtures, equipment used in research and development and electronic processing equipment.

Information on Kentucky’s economic development efforts and programs is available at Fans of the Cabinet for Economic Development can also join the discussion on Facebook at or follow on Twitter at Watch the Cabinet’s “This is My Kentucky” video at

Most Recent

comments powered by Disqus